William Blair Remains Bullish on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst Matt Phipps reiterated a bullish stance on Genmab A/S (NASDAQ:GMAB), giving the stock a Buy rating without assigning a price target.

The analyst supported the rating with the company’s solid financial performance and promising pipeline developments, stating that Genmab A/S (NASDAQ:GMAB) surpassed both consensus and internal revenue estimates, reporting strong fiscal Q2 results.

He attributed the growth to a notable sales growth of Epkinly and robust royalties from Darzalex and Kesimpta.

The company’s financial strength prompted an upward revision of the full-year revenue guidance, suggesting increased confidence in solid performance by Genmab A/S (NASDAQ:GMAB), the analyst added.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases.

Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.